N-Acetyl-Cysteine

Phase 2

UUniversity of California, Irvine

N-Acetyl-Cysteine is one of 51 therapeutic programs targeting Cornelia de Lange syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Cornelia De Lange SyndromeNot yet recruiting

Ovarian CancerRecruiting

Cornelia De Lange SyndromePhase 2

Not yet recruiting

Ovarian CancerPreclinical

Recruiting

Competition

Competitive Landscape

207 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

92 2

Gemzar

Johnson & Johnson

Phase 3

33 3

Hycamtin

MMeitheal

Phase 3

26 4

Pegylated Liposomal Doxorubicin

Merck & Co.

Phase 3

35 5

Cytoxan

BBaxter Healthcare Corporation

Phase 3

24 6

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

24 7

Adriamycin

Pfizer

Phase 3

8 8

Lynparza

RRisen (Suzhou) Pharma Tech Co., Ltd.

Phase 3

14 9

Herceptin

Roche

Phase 3

3 10

Zepzelca

Jazz Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Not yet recruiting

Cornelia De Lange Syndrome

NCT04381897

Q4 2027

PreclinicalRecruiting

Ovarian Cancer

NCT04520139

Phase 3Recruiting

Influenza

NCT03900988

Q4 2029

Phase 2Recruiting

Schizoaffecitve Disorder

NCT07759895

Q3 2031

Phase 2Not yet recruiting

Bipolar Disorder

NCT07913542

Clinical

Trials by Indication[1]

Bipolar Disorder1 trial

N-acetylcysteine for Restoring Glutamate/Glutathione Homeostasis and Reducing Heavy Drinking in Co-occurring Bipolar and Alcohol Use Disorders

Not yet recruiting·MMedical University of South Carolina·Phase 2·NCT07913542·70 enrolled

Polycystic Ovary Syndrome1 trial

The Combined Effect of N-Acetyl Cysteine and Metformin in Polycystic Ovary Syndrome Patients

Completed·CCairo University·Phase 3·NCT06836128·102 enrolled

Influenza1 trial

A Randomized, Double Blind, Placebo Controlled Trial of Intravenous N-acetylcysteine and Oseltamivir Versus Intravenous 5% Dextrose and Oseltamivir in Adults Hospitalized With Influenza Complicated by Lower Respiratory Tract Infection.

Recruiting·CChinese University of Hong Kong·Phase 3·NCT03900988·160 enrolled

Schizoaffecitve Disorder1 trial

Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in Schizophrenia

Recruiting·AAmit Lotan·Phase 2·NCT07759895·80 enrolled

Cornelia de Lange syndrome1 trial

Use of N-Acetylcysteine (NAC) in the Treatment of Repetitive Behaviors (RB) and Self-Injurious Behaviors (SIB) in Cornelia de Lange Syndrome: A Randomized Double-Blind Placebo-Controlled Pilot Study

Not yet recruiting·JJohns Hopkins University·Phase 2·NCT04381897·10 enrolled

3 more indications

Cannabis Use1 trial

N-Acetylcysteine for Smoking Cessation in Tobacco and Cannabis Co-Use: A Randomized Controlled Trial

Completed·EEllen Herbst·Approved·NCT04627922·41 enrolled

Progressive Multiple Sclerosis1 trial

A Phase 2 Randomized, Placebo- Controlled, Parallel Group, Double Blinded Single Center Study on Effect of N-acetyl Cysteine Compared to Placebo on Fatigue in Patients With Progressive Multiple Sclerosis

Completed·UUniversity of California, San Francisco·Phase 2·NCT02804594·15 enrolled

Ovarian Cancer1 trial

Phase I Dose-Escalating and Phase II Dose-Expansion Study of N-Acetyl-Cysteine (NAC) Administration to Ovarian Cancer Patients Receiving Platinum-Based Therapy (PBT) for the Mitigation of Chemotherapy-Related Cognitive Impairment (CRCI)

Recruiting·UUniversity of California, Irvine·Preclinical·NCT04520139·102 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for N-Acetyl-Cysteine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for N-Acetyl-Cysteine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of California, Irvine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: UUniversity of California, Irvine

N-Acetyl-Cysteine

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Q4 2029

Q3 2031

Trials by Indication[1]

Bipolar Disorder1 trial

Polycystic Ovary Syndrome1 trial

Influenza1 trial

Schizoaffecitve Disorder1 trial

Cornelia de Lange syndrome1 trial

Cannabis Use1 trial

Progressive Multiple Sclerosis1 trial

Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News